Ovarian hyperstimulation syndrome prevention strategies: Individualizing gonadotropin dose

Seminars in Reproductive Medicine

Volumn 28, Issue 6, 2010, Pages 463-467

  Olivennes, François ^a  

^a IVF Center Eylau la Muette   (France)

Author keywords

gonadotropin; individualization; Ovarian hyperstimulation syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; RECOMBINANT FOLLITROPIN;

AGE; ALGORITHM; BODY MASS; DRUG DOSE REDUCTION; FERTILIZATION IN VITRO; HUMAN; LOW DRUG DOSE; OOCYTE; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY RATE; REVIEW; SCORING SYSTEM;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; GONADOTROPINS; HUMANS; INDIVIDUALIZED MEDICINE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY;

EID: 78649302321     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0030-1265672     Document Type: Review

References (34)

1. Marci R, Senn A, Dessole S et al. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil Steril 2001 75 (6) 1131-1135
2. Tan S L., Child T J., Cheung A P. et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J Assist Reprod Genet 2005 22 (2) 81-88
3. Latin-American Puregon IVF Study Group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil Steril 2001 76 (5) 950-956
4. Out H J., Lindenberg S, Mikkelsen A L. et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999 14 (3) 622-627
5. Out H J., Rutherford A, Fleming R et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004 19 (1) 90-95
6. Wikland M, Bergh C, Borg K et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001 16 (8) 1676-1681
7. Yong P Y., Brett S, Baird D T., Thong K J. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril 2003 79 (2) 308-315
8. Forman R G., Frydman R, Egan D, Ross C, Barlow D H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 1990 53 (3) 502-509
9. Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril 2002 77 (4) 711-714
10. Filicori M, Cognigni G E., Samara A et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 2002 8 (6) 543-557
11. Lee K L., Couchman G M., Walmer D K. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation. J Assist Reprod Genet 2005 22 (1) 37-40
12. Filicori M, Cognigni G E., Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 2005 84 (2) 394-401
13. Blockeel C, De Vos M, Verpoest W, Stoop D, Haentjens P, Devroey P. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study. Hum Reprod 2009 24 (11) 2910-2916
14. Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod Biol Endocrinol 2003 1 109
15. Rongières-Bertrand C, Olivennes F, Righini C et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999 14 (3) 683-688
16. Pelinck M J., Vogel N E., Arts E G., Simons A H., Heineman M J., Hoek A. Cumulative pregnancy rates after a maximum of nine cycles of modified natural cycle IVF and analysis of patient drop-out: a cohort study. Hum Reprod 2007 22 (9) 2463-2470
17. Popovic-Todorovic B, Loft A, Bredkjaeer H E., Bangsbøll S, Nielsen I K., Andersen A N. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a standard dose of 150 IU/day in standard patients undergoing IVF/ICSI treatment. Hum Reprod 2003 18 (11) 2275-2282
18. Yih M C., Spandorfer S D., Rosenwaks Z. Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories. Fertil Steril 2005 83 (1) 24-29
19. van der Gaast M H., Eijkemans M J., van der Net J B. et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 2006 13 (4) 476-480
20. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002 8 (6) 559-577 (Pubitemid 35452781)
21. van Noord-Zaadstra B M., Looman C W., Alsbach H, Habbema J D., te Velde E R., Karbaat J. Delaying childbearing: effect of age on fecundity and outcome of pregnancy. BMJ 1991 302 (6789) 1361-1365
22. Wright V C., Schieve L A., Reynolds M A., Jeng G, Kissin D. Assisted reproductive technology surveillanceUnited States, 2001. MMWR Surveill Summ 2004 53 (1) 1-20
23. Abdalla H, Thum M Y. Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH. Hum Reprod 2006 21 (1) 171-174
24. Verberg M F., Eijkemans M J., Macklon N S., Heijnen E M., Fauser B C., Broekmans F J. Predictors of low response to mild ovarian stimulation initiated on cycle day 5 for IVF. Hum Reprod 2007 22 (7) 1919-1924
25. Broekmans F J., Kwee J, Hendriks D J., Mol B W., Lambalk C B. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006 12 (6) 685-718
26. Bancsi L F., Broekmans F J., Looman C W., Habbema J D., te Velde E R. Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization. Fertil Steril 2004 81 (1) 35-41
27. Bancsi L F., Broekmans F J., Mol B W., Habbema J D., te Velde E R. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 2003 79 (5) 1091-1100
28. Popovic-Todorovic B, Loft A, Lindhard A, Bangsbøll S, Andersson A M., Andersen A N. A prospective study of predictive factors of ovarian response in standard IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003 18 (4) 781-787
29. Fleming R, Deshpande N, Traynor I, Yates R W. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 2006 21 (6) 1436-1441
30. Howles C M., Saunders H, Alam V, Engrand P, FSH Treatment Guidelines Clinical Panel. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients. Curr Med Res Opin 2006 22 (5) 907-918
31. Olivennes F, Howles C M., Borini A et al, CONSORT study group. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2009 18 (2) 195-204
32. Hohmann F P., Macklon N S., Fauser B C. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003 88 (1) 166-173
33. Heijnen E M., Eijkemans M J., De Klerk C et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007 369 (9563) 743-749
34. Baart E B., Martini E, Eijkemans M J. et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007 22 (4) 980-988